San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
The significance of a deal announced last week during the 2015 International CES in Las Vegas went largely unnoticed amid the hubbub of the world’s biggest consumer technology show, packed as it was…
[[Click headline to continue reading.]]
SAN FRANCISCO, CA, Jan. 14, 2015 /PRNewswire/ – Resverlogix Corp. (TSX:RVX) (the “Company”) today announced that Donald McCaffrey, president and chief executive officer presented at the 7th Annual Biotech Showcase Conference 2015 during JP Morgan week. The presentation can be accessed via the following link: http://edge.media-server.com/m/p/5wz2z9gn
Mr. McCaffrey was excited to share developments of the Company’s proposed new phase 3 clinical trial BETONMACE. “This trial represents an unprecedented opportunity to reduce major adverse coronary events “MACE” in patients with diabetes. RVX-208 is the only selective BET-Bromodomain inhibitor in clinical trials to reduce the risk of death by cardiac events in patients with CVD and diabetes.”
RVX-208 is a first-in-class, small molecule selective BET bromodomain inhibitor. BET-Bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes either on or off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with important benefits for patients with disease such as cardiovascular disease, diabetes mellitus, Alzheimer’s disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with diabetes mellitus and low HDL.
Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer’s disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix’s common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of cardiovascular disease, Alzheimer’s disease, peripheral artery disease and chronic kidney disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Donald J. McCaffrey
President and CEO
Director, Investor Relations & Corporate Communications
SOURCE Resverlogix Corp.
Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of SamplesLA JOLLA, Calif., Jan. 14, 2015 /PRNewswire/ — Human Longevity, Inc. (HLI), the human health information technology and health care company, today announced a multi-year…
Adamis Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Exercise Of Over-Allotment Option In Full
SAN DIEGO, Jan. 14, 2015 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical…
Temporary Tattoo Offers Needle-Free Way To Monitor Glucose Levels, University of California, San Diego (UCSD) Study
Nanoengineers at the University of California, San Diego have tested a temporary tattoo that both extracts and measures the level of glucose in the fluid in between skin cells. This first-ever example of the flexible, easy-to-wear device could be a pro…
Auspex Pharmaceuticals Receives FDA Orphan Drug Designation Of SD-809 For Treatment Of Tourette Syndrome In The Pediatric Population
LA JOLLA, Calif., Jan. 14, 2015 (GLOBE NEWSWIRE) — Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that th…
Taxus Cardium Elects Three New Board Members Including PRC Strategic Investor U.S. Equity Trading Services Executive, And International Gene Therapy Pioneer
SAN DIEGO, Jan. 15, 2015 /PRNewswire/ — Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the election of the following three new directors: Mr. Jiayue Zhang, President of Shanxi Taxus Pharmaceuticals Co. Ltd. (Shanxi Tax…
SAN DIEGO, Jan. 14, 2015 /PRNewswire/ –GenomeDx Biosciences today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has issued a positive coverage policy through the MolDX Program for the company’s Decipher prostat…
SAN DIEGO, CA–(Marketwired – January 14, 2015) – Regen BioPharma Inc. (OTCBB: RGBP) provided the following update on the Company’s direction for 2015:The Company currently has augmented its activities in the area of gene silencing for treating can…
Clinical Study Results Presented At The 2015 Gastrointestinal Cancer Symposium Support Utility Of Trovagene’s Precision Cancer Monitoring Platform In Colorectal And Pancreatic Cancer Patients
SAN DIEGO, Jan. 20, 2015 /PRNewswire/ –Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced the presentation of results from two clinical studies at the 2015 Gastrointestinal Cancer Symposium (also known as ASCO GI…